{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,17]],"date-time":"2025-12-17T21:16:28Z","timestamp":1766006188759,"version":"3.48.0"},"reference-count":19,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,9,15]],"date-time":"2025-09-15T00:00:00Z","timestamp":1757894400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004399","name":"UCB Pharma GmbH","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004399","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006484","name":"AbbVie Deutschland GmbH & Co KG","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006484","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004336","name":"Novartis AG","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006676","name":"Lilly Deutschland GmbH","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006676","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100018592","name":"Celltrion Pharma","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100018592","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002429","name":"Amgen Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002429","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005614","name":"Biogen Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005614","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004319","name":"Pfizer Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008897","name":"Janssen Pharmaceuticals Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008897","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["ero.eular.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["EULAR Rheumatology Open"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1016\/j.ero.2025.09.004","type":"journal-article","created":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T20:40:20Z","timestamp":1760560820000},"page":"312-318","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Which are the clinical characteristics that lead to the decision of primary or secondary usage of TNFi or IL-17i in patients with axial spondyloarthritis?: Real-world evidence from the RABBIT-SpA cohort"],"prefix":"10.1016","volume":"1","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2456-4049","authenticated-orcid":false,"given":"Anne C.","family":"Regierer","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2069-2190","authenticated-orcid":false,"given":"Anja","family":"Wei\u00df","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas","family":"Marycz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karin","family":"Manger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martin","family":"Bohl-B\u00fchler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9475-9362","authenticated-orcid":false,"given":"Xenofon","family":"Baraliakos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.ero.2025.09.004_bib0001","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1136\/ard-2022-223296","article-title":"ASAS-EULAR recommendations for the management of axial spondyloarthritis: 2022 update","volume":"82","author":"Ramiro","year":"2023","journal-title":"Ann Rheum Dis"},{"issue":"10","key":"10.1016\/j.ero.2025.09.004_bib0002","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2024.103638","article-title":"Treatment strategies for Spondyloarthritis: Implementation of precision medicine\u2014or \"one size fits all\" concept?","volume":"23","author":"Proft","year":"2024","journal-title":"Autoimmun Rev"},{"issue":"11","key":"10.1016\/j.ero.2025.09.004_bib0003","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1007\/s40264-024-01461-1","article-title":"A systematic overview of contraindications and special warnings for biologic and targeted synthetic disease modifying antirheumatic drugs: establishing a framework to create a \"safety checklist\"","volume":"47","author":"Skaarup","year":"2024","journal-title":"Drug Saf"},{"issue":"1","key":"10.1016\/j.ero.2025.09.004_bib0004","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1186\/s13075-021-02563-2","article-title":"Implementing an automated monitoring process in a digital, longitudinal observational cohort study","volume":"23","author":"Lindner","year":"2021","journal-title":"Arthritis Res Ther"},{"issue":"2","key":"10.1016\/j.ero.2025.09.004_bib0005","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1007\/s00393-019-0613-z","article-title":"RABBIT-SpA: a new disease register for axial spondyloarthritis and psoriatic arthritis","volume":"79","author":"Regierer","year":"2020","journal-title":"Z Rheumatol"},{"issue":"10","key":"10.1016\/j.ero.2025.09.004_bib0006","doi-asserted-by":"crossref","first-page":"2199","DOI":"10.1002\/acr.25116","article-title":"Updating and validating the rheumatic disease comorbidity index to incorporate ICD-10-CM diagnostic codes","volume":"75","author":"Dolomisiewicz","year":"2023","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"6","key":"10.1016\/j.ero.2025.09.004_bib0007","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1002\/acr.22456","article-title":"Validation of the rheumatic disease comorbidity index","volume":"67","author":"England","year":"2015","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"381","key":"10.1016\/j.ero.2025.09.004_bib0008","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1080\/01621459.1983.10477938","article-title":"Binomial confidence intervals","volume":"78","author":"Blyth","year":"1983","journal-title":"J Am Stat Assoc"},{"issue":"2","key":"10.1016\/j.ero.2025.09.004_bib0009","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2017-000524","article-title":"Switching biological disease-modifying antirheumatic drugs in patients with axial spondyloarthritis: results from a systematic literature review","volume":"3","author":"Navarro-Compan","year":"2017","journal-title":"RMD Open"},{"issue":"1","key":"10.1016\/j.ero.2025.09.004_bib0010","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2021-001846","article-title":"Evaluation of long-term TNFi effectiveness after a first switch in early axial spondyloarthritis considering time-varying prescription bias: an inverse-probability weighting analysis of the DESIR cohort","volume":"8","author":"Pons","year":"2022","journal-title":"RMD Open"},{"issue":"1","key":"10.1016\/j.ero.2025.09.004_bib0011","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1186\/s13075-019-1908-9","article-title":"Biological treatment of ankylosing spondylitis: a nationwide study of treatment trajectories on a patient level in clinical practice","volume":"21","author":"Lindstrom","year":"2019","journal-title":"Arthritis Res Ther"},{"issue":"3","key":"10.1016\/j.ero.2025.09.004_bib0012","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2020-001280","article-title":"Drug retention, inactive disease and response rates in 1860 patients with axial spondyloarthritis initiating secukinumab treatment: routine care data from 13 registries in the EuroSpA collaboration","volume":"6","author":"Michelsen","year":"2020","journal-title":"RMD Open"},{"issue":"7","key":"10.1016\/j.ero.2025.09.004_bib0013","doi-asserted-by":"crossref","first-page":"1882","DOI":"10.1093\/rheumatology\/kead494","article-title":"Second and third TNF inhibitors in European patients with axial spondyloarthritis: effectiveness and impact of the reason for switching","volume":"63","author":"Linde","year":"2024","journal-title":"Rheumatology (Oxford)"},{"issue":"5","key":"10.1016\/j.ero.2025.09.004_bib0014","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1002\/acr.24523","article-title":"One-year treatment outcomes of secukinumab versus tumor necrosis factor inhibitors in spondyloarthritis: results from five nordic biologic registries including more than 10,000 treatment courses","volume":"74","author":"Glintborg","year":"2022","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"9","key":"10.1016\/j.ero.2025.09.004_bib0015","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2024-087872","article-title":"Rotation or change of biotherapy after TNF blocker treatment failure for axial spondyloarthritis: the ROC-SpA study, a randomised controlled study protocol","volume":"14","author":"Dalix","year":"2024","journal-title":"BMJ Open"},{"issue":"9","key":"10.1016\/j.ero.2025.09.004_bib0016","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1136\/annrheumdis-2019-215934","article-title":"Effectiveness of secukinumab versus an alternative TNF inhibitor in patients with axial spondyloarthritis previously exposed to TNF inhibitors in the Swiss Clinical Quality Management cohort","volume":"79","author":"Micheroli","year":"2020","journal-title":"Ann Rheum Dis"},{"issue":"10","key":"10.1016\/j.ero.2025.09.004_bib0017","doi-asserted-by":"crossref","first-page":"2057","DOI":"10.1007\/s00296-024-05671-9","article-title":"Analysis of the shorter drug survival times for Janus kinase inhibitors and interleukin-17 inhibitors compared with tumor necrosis factor inhibitors in a real-world cohort of axial spondyloarthritis patients\u2014a retrospective analysis from the RHADAR network","volume":"44","author":"Strunz","year":"2024","journal-title":"Rheumatol Int"},{"issue":"Suppl 1","key":"10.1016\/j.ero.2025.09.004_bib0018","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1136\/annrheumdis-2024-eular.2308","article-title":"OP0081\u2005comparison of cycle versus swap treatment strategy on drug retention and disease activity after tnfi failure in axial spondyloarthritis: a quasi-experimental study","volume":"83","author":"Van Es","year":"2024","journal-title":"Ann Rheum Dis"},{"issue":"10473","key":"10.1016\/j.ero.2025.09.004_bib0019","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/S0140-6736(24)02263-3","article-title":"Axial spondyloarthritis","volume":"405","author":"Navarro-Compan","year":"2025","journal-title":"Lancet"}],"container-title":["EULAR Rheumatology Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S305070812500076X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S305070812500076X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,12,17]],"date-time":"2025-12-17T21:12:56Z","timestamp":1766005976000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S305070812500076X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10]]},"references-count":19,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,10]]}},"alternative-id":["S305070812500076X"],"URL":"https:\/\/doi.org\/10.1016\/j.ero.2025.09.004","relation":{},"ISSN":["3050-7081"],"issn-type":[{"type":"print","value":"3050-7081"}],"subject":[],"published":{"date-parts":[[2025,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Which are the clinical characteristics that lead to the decision of primary or secondary usage of TNFi or IL-17i in patients with axial spondyloarthritis?: Real-world evidence from the RABBIT-SpA cohort","name":"articletitle","label":"Article Title"},{"value":"EULAR Rheumatology Open","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ero.2025.09.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier B.V. on behalf of European Alliance of Associations for Rheumatology (EULAR).","name":"copyright","label":"Copyright"}]}}